Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 34
Growth opportunities supported by strong global presence
in both sales and manufacturing
FTEs in sales regions¹
North America Operations:
Region Africa, Asia, Middle-East
and Oceania (AAMEO):
Region China:
Region Europe:
Region Japan & Korea:
Region Latin America:
Total non-HQ/manufacturing FTEs:
~4,800
West Lebanon, NH,
USA (~180 FTEs)
~4,600
Biopharmaceutical
API production
~3,000
~2,800
~1,200
~900
~19,000¹
Global manufacturing setup
Denmark (~9,750 FTEs)
Diabetes and biopharmaceutical
API production
Filling and packaging
Moulding and assembly
Tablet production
Kaluga, Russia (~250 FTEs)
Filling
Assembly
Packaging
Clayton, NC, USA
(~1,000 FTEs)
Diabetes API production
Filling
Assembly
Packaging of above
Chartres, France
(~1,100 FTEs)
Filling
Assembly
Packaging
Montes Claros, Brazil
(~1,000 FTEs)
Filling
Assembly
Packaging
Tizi Ouzou, Algeria
(~150 FTEs)
Tablet production
1 FTEs represent full-time equivalents in Novo Nordisk's sales regions (excludes all other employees in headquarter, research sites and manufacturing sites) as of Dec 2017
changing
diabetes
Koriyama, Japan (~70 FTEs)
Packaging
Tianjin, China (~1,000 FTEs)
Filling
Assembly
Packaging
novo nordiskView entire presentation